African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2277

Full Length Research Paper

Enalaprilat-induced cardiac fibroblast proliferation via regulation of transforming growth factor beta 1 (TGF-β1)-expressing anti-angiotensin II (Ang II)

Du-Juan Yu1, Li-Jun Xu1*, Min Yu1,2* and Hong-Xia Sun3
1Department of Respiratory, First Clinical Hospital of Jilin University, Changchun, 130021, China. 2Department of Cardiology, Affiliated Hospital of Bei-hua University, Jilin, 132011, China. 3Department of Pharmacology, College of Pharmacy, Beihua University, Jilin 132013, China.
Email: [email protected], [email protected]

  •  Accepted: 16 May 2012
  •  Published: 08 July 2012

Abstract

The objectives of this study were to investigate the effects of the angiotensin I-converting enzyme inhibitor enalaprilat (Ena) on the proliferation, hydroxyproline content, and transforming growth factor β1 (TGF-β1) protein expression of neonatal cardiac fibroblasts and to probe its anti-cardiac fibrosis mechanism. Cardiac fibroblast (CFb) was isolated using the trypsin digestion method. Methyl thiazolyl tetrazolium (MTT) colorimetric assay was performed to evaluate cell proliferation, a hydroxyproline method of determination was used to measure collagen content, and reverse transcription-polymerase chain reaction and flow cytometry were used to detect mRNA TGF-β1 and protein levels, respectively, with Ena. Ena decreased dramatically the MTT value, the hydroxyproline content, and inhibited TGF-β1 transcription and protein expression in neonatal rat CFb. The antiproliferative effects of Ena on CFb may be attributed to the inhibition of TGF-β1 transcription and protein expression in cardiac fibroblasts and the antagonistic action of angiotensin II (Ang II).

 

Key words: Enalaprilat, cardiac fibroblast, hydroxyproline, transforming growth factor-β1.